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Abstract: Background: Clinacanthus nutans (C. nutans) is an Acanthaceae herbal shrub traditionally
consumed to treat various diseases including diabetes in Malaysia. This study was designed
to evaluate the α-glucosidase inhibitory activity of C. nutans leaves extracts, and to identify the
metabolites responsible for the bioactivity. Methods: Crude extract obtained from the dried
leaves using 80% methanolic solution was further partitioned using different polarity solvents.
The resultant extracts were investigated for their α-glucosidase inhibitory potential followed by
metabolites profiling using the gas chromatography tandem with mass spectrometry (GC-MS).
Results: Multivariate data analysis was developed by correlating the bioactivity, and GC-MS
data generated a suitable partial least square (PLS) model resulting in 11 bioactive compounds,
namely, palmitic acid, phytol, hexadecanoic acid (methyl ester), 1-monopalmitin, stigmast-5-ene,
pentadecanoic acid, heptadecanoic acid, 1-linolenoylglycerol, glycerol monostearate, alpha-tocospiro
B, and stigmasterol. In-silico study via molecular docking was carried out using the crystal
structure Saccharomyces cerevisiae isomaltase (PDB code: 3A4A). Interactions between the inhibitors
and the protein were predicted involving residues, namely LYS156, THR310, PRO312, LEU313,
GLU411, and ASN415 with hydrogen bond, while PHE314 and ARG315 with hydrophobic bonding.
Conclusion: The study provides informative data on the potential α-glucosidase inhibitors identified
in C. nutans leaves, indicating the plant’s therapeutic effect to manage hyperglycemia.
Keywords: α-glucosidase inhibitors; Clinacanthus nutans; diabetes; GC-MS; partial least square
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1. Introduction
Diabetes mellitus (DM) is one of the most chronic metabolic disorders that occurs due to abnormal
carbohydrate metabolism that is mainly linked with insensitivity of the target organs to insulin [1,2].
Commonly, it is characterized by hyperglycemia in which the level of blood sugar is significantly
elevated, which in turn disturbs the normal body metabolism related to carbohydrate, fat, and protein
breakdown and eventually proves fatal if not treated or managed properly [3]. Cases of DM are
increasing rapidly worldwide and affecting all parts of the world. High increasing numbers of cases
have been reported in most developing countries, including Malaysia; caused mainly by inactive
lifestyle and unhealthy food consumption [4]. Around 170 million people worldwide had diabetes in
the year of 2000 and it is projected to increase to 366 million by 2030 [5]. Additionally, the prevalence
of DM is also rapidly rising among the middle-class and low-income communities in developing
countries [6].
The use of several traditional medicinal plants in the treatment of diabetes has been reported [7,8].
Likewise, Clinacanthus nutans (Burm. F) Lindau; (C. nutans) or Sabah snake grass (locally known as
‘belalai gajah’), is a herbal shrub found abundantly in some Asian countries including Thailand and
Malaysia. This herb has been traditionally used to treat various diseases including gout, hyperuricemia,
inflammation, fever, skin rashes, and diabetes [9]. Commonly, the plant leaves are used for the
treatment of burns, allergic reactions, mucositis, skin rashes, and lesions of varicella-zoster virus (VZV)
and herpes simplex virus (HSV) [10,11]. In Malaysia and Thailand, it has been practiced as a remedy
for scorpion and insect stings as well as venomous snake bites [12,13]. In recent times, the leaves
of C. nutans are widely consumed by cancer patients throughout Malaysia [14] while in Indonesia,
the leaves are used to treat diabetes, hyperuricemia, and dysentery [15,16].
C. nutans leaves are reported to contain several compounds that possess hypoglycemic properties
such as caffeic acid, chlorogenic acid, quercetin, lupeol, betulin, stigmasterol, and β-sitosterol [17–20].
Most of the existing studies were carried out separately to evaluate the biological activities of some
individual compounds. However, the bioactivity of the individual compounds may be different when
these compounds are within the complex matrix of the leaves, which could be due to the synergistic
effect with other components [21]. Thus, the reported antidiabetic compounds may not be solely
responsible for the actual antidiabetic activity of the plant. Therefore, one way of detecting the
compounds responsible for a given activity is by using the metabolomics approach. It is a holistic
approach that includes the detection of all metabolites in each sample that can be correlated to the
tested bioactivity using multivariate data analysis (MVDA) [22]. Metabolomics techniques can be
achieved with the aid of chromatography or spectroscopy instruments to profile all the metabolites
present in the analyzed sample. MVDA is a suitable statistical tool for managing large data sets
obtained using spectroscopic tools and is employed in classifying samples based on their chemical
constituents [23].
Several common analytical instruments have been used as an analytical platform in metabolomics,
including nuclear magnetic resonance spectroscopy (NMR), gas chromatography-mass spectrometry
(GC-MS), and liquid chromatography-mass spectrometry (LC-MS) [24]. In this study, GC-MS was
utilized due to the non-polar nature of the most active hexane extract. Moreover, GC-MS provides
high resolution of separation, high sensitivity, and the reproducibility needed to analyze a complex
biological mixture [25]. Hence, the aims of this study were to evaluate the α-glucosidase inhibitory
activity of different extracts of C. nutans leaves, and to identify the related bioactive compounds in the
extract using GC-MS based metabolomics.
The study has also depicted the molecular interaction between the enzymes and the inhibitors
(ligands) identified in the plant extracts. With molecular docking, the conformations and binding
affinities of the potential phytoconstituents could be predicted. In addition, this in-silico technique aids
in the visualization of the ligand-protein complex formed while portraying the characteristic activity
and binding sites of the compounds [26].
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2. Results
2.1. α-Glucosidase Inhibitory Activity
The α-glucosidase inhibitory activity of the C. nutans leaves extracts obtained from different
solvent extraction are displayed in Table 1 as the half-maximal concentration values (IC50, µg/mL).
A lower IC50 value is desirable for higher α-glucosidase inhibition activity [27]. The IC50 values ranged
from 3.07 to 133.57 µg/mL. The highest α-glucosidase inhibitory activity was observed for hexane
fraction, with an IC50 value of 3.05 µg/mL, which was found comparable or even better to the IC50
value obtained for quercetin, the positive control. Meanwhile, the methanol extract exhibited the
lowest activity with the highest IC50 viz., 133.57 µg/mL.
Table 1. The half maximal inhibitory concentration (IC50) of α-glucosidase inhibitory activity of
C. nutans leaves extracts.
Samples IC50 (µg/mL)
Hexane (H) 3.05 ± 0.05 d
Hexane: Ethyl acetate (HE) 5.54 ± 0.09 d
Ethyl acetate (EA) 8.42 ± 0.17 c
Ethyl acetate: Methanol (EAM) 37.45 ± 0.90 b
Methanol (M) 133.57 ± 0.30 a
Quercetin 5.77 ± 1.01(19.09 µM)
Data expressed as mean ± SD (n = 6). SD = Standard Deviation. Means that do not share a letter are significantly
different with p value < 0.05.
2.2. GC-MS Chromatogram of C. nutans Leaves Extracts
All identified metabolites were confirmed by scrutinizing the spectral pattern and comparison
with GC-MS NIST14 database library. The metabolites identified were primarily plant sterols,
fatty acids, organic acids, and others, including palmitic acid, phytol, hexadecanoic acid,
1-monopalmitin, stigmast-5-ene, pentadecanoic acid, heptadecanoic acid, 1-linolenoylglycerol, glycerol
monostearate, alpha-tocospiro B and stigmasterol. The remaining compounds include sucrose, maltose,
D-gluconic acid and D-glucose, which were abundant in the non-active extract (methanol extract).
All the above-mentioned metabolites are labelled and shown in the chromatogram of each of the extract
analyzed, as displayed in Figure 1. Several compounds are found abundantly in H, HE and E extracts
especially palmitic acid, phytol, stigmast-5-ene and stigmasterol. The intensity of the metabolites
reduced apparently as the polarity of the extract solvent increased. Meanwhile, sucrose and D-glucose
were found more prominent in the more polar extract (EM and M).
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Figure 1. GC-MS chromatogram of metabolites in H, HE, E, EA and M extracts from C. nutans.
Each labelled peak refers to; 1—palmitic acid, 2—phytol, 3—sucrose, 4—hexadecanoic acid, 5—maltose,
6—1-monopalmitin, 7—D-glucose, 8—stigmast-5-ene, 9—D-gluconic acid, 10—pentadecanoic acid,
11—heptadecanoic acid, 12—1-Linolenoylglycerol, 13—Glycerol monostearate, 14—Alpha-Tocospiro B
and 15—Stigmasterol.
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2.3. Multivariate Data Analysis
The bioactive compounds can be identified through GC-MS based metabolomics utilizing MVDA
whereby a partial least square (PLS) model was developed. Automated fitting results in two principal
components namely PLS component 1 and 2. The mass to charge ratio (m/z) of a certain retention
time was extracted and the IC50 (µg/mL) values of each of the samples were considered as x and y
variables, respectively. PLS was performed to discriminate the constituents among the extracts and to
pinpoint the m/z values contributing to the bioactivity [1]. Briefly, the model diagnostic of the PLS
model developed can be evaluated using several parameters such as goodness of fit, permutation test,
and capability of the model to predict the y value using actual to predicted plot. The goodness of fit
is explained by the cumulative values of R2Y indicating the percentage of variation of the response
explained by the model, and the cumulative value of Q2Y representing the percentage of the variation
of the response predicted by the model according to cross validation. The fitness of model and
predictive ability are considered good if the cumulative values of both R2Y and Q2Y are greater than
0.5 [28]. In this study, the R2Y and Q2Y values were 0.95 and 0.87, respectively.
Other important parameters that are considered in measuring the accuracy and the performance
of the model are root-mean-square errors of estimation (RMSEE) and the root mean square error of
cross-validation (RMSECV). RMSEE is a measure of average deviation of the model from the data,
while RMSECV is a measure of the quality of the model in predicting new samples. The lower the
RMSECV value, the higher the predictive accuracy for new samples. For this model, the RMSEE and
the RMSECV values are 0.0286046 and 0.0441324, respectively.
Figure 2 shows the score scatter plot of the PLS model with good separation of the samples based
on the chemical profile and bioactivity (IC50 value) of the samples. The high active samples (H, HE,
and EA) with the IC50 value less than 10 µg/mL were observed at the positive PLS component 1,
while the less active samples (EAM and M) were distributed at the negative PLS component 1.
Figure 2. Partial least square (PLS) score scatter plot of different solvent extracts of C. nutans leaves.
Figure 3 displays the permutation test plot, which depicts the validation of the PLS model
developed. The plot displays the intercepts for the fraction of the total sum of the squares intercept
Y-value and the predictive ability of the model intercept Y-value. The R2Y and Q2Y values in this
study are 0.407 and −0.288, respectively, which are acceptable since the R2 and Q2 is equal or less
than 0.4 and −0.05, respectively [29]. The supplementary plot, Figure S1 displays the observed versus
predicted plot that measures the accuracy of the PLS model with the regression equation that measures
its validation with R2 value of 0.9497, which is valid only if the R2 value is ≥ 0.9.
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Figure 3. The permutation plot with the R2Y = 0.407 and Q2Y = −0.288.
Figure 4 shows the loading column plot of the different extracts of C. nutans leaves. Each peak
indicates the identified metabolite from the C. nutans leaves extracts and the compounds details have
been tabulated in Table 2. The peaks labelled as 3, 5, 7, and 9 represent sucrose, maltose, D-gluconic
acid, and D-glucose, respectively, that are located opposite to the per IC50 value assumed to induce
α-glucosidase activity. These compounds were found abundant in the methanol extract, with its
IC50 value more than 100 µg/mL. Meanwhile, the rest of the peaks that are in the same position as
the per IC50 value are effective to inhibit α-glucosidase activity which are primarily plant sterols,
fatty acids, organic acids, and other compounds, namely; palmitic acid, phytol, hexadecanoic acid,
1-monopalmitin, stigmast-5-ene, pentadecanoic acid, heptadecanoic acid, 1-linolenoylglycerol, glycerol
monostearate, alpha-tocospiro B, and stigmasterol (Figure 5).
Figure 4. PLS loading column plot of different solvent extracts of C. nutans leaves. Assignments:
1—Palmitic Acid, 2—Phytol, 3—Sucrose, 4—Hexadecanoic acid, 5—Maltose, 6—1-Monopalmitin,
7—D-Glucose, 8—Stigmast-5-ene, 9—D-Gluconic acid, 10—Pentadecanoic acid, 11—Heptadecanoic acid,
12—1-Linolenoylglycerol, 13—Glycerol monostearate, 14—alpha-Tocospiro B, and 15—Stigmasterol.
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Table 2. Compounds identified in the C. nutans leaves extracts through GC-MS analysis.
No. RT (min) % of Area Probability M+ MolecularFormula Tentative Metabolites
1 17.24 10.50 99 256.24 C16H32O2 Palmitic acid
2 26.64 1.42 95 296.31 C20H40O Phytol
3 45.47 36.18 93 342.12 C12H22O11 Sucrose
4 11.63 0.91 99 270.26 C17H34O2 Hexadecanoic acid
5 49.48 0.28 93 342.12 C12H22O11 Maltose
6 44.43 1.03 95 330.51 C19H38O4 1-Monopalmitin
7 10.31 19.04 91 180.06 C6H12O6 D-Glucose
8 56.83 4.50 99 398.39 C29H50 Stigmast-5-ene
9 14.30 3.42 93 196.16 C6H12O7 D-Gluconic acid
10 12.34 0.24 98 242.22 C15H30O2 Pentadecanoic acid
11 23.95 0.38 93 270.26 C17H34O2 Heptadecanoic acid
12 47.59 0.46 99 352.52 C17H36O 1-Linolenoylglycerol
13 47.99 0.40 91 358.31 C21H42O4 Glycerol monostearate
14 49.24 0.07 96 462.37 C29H50O4 Alpha-Tocospiro B
15 55.59 2.70 99 412.37 C29H48O Stigmasterol
RT = Retention Time C = Carbon, H = Hydrogen, O = Oxygen, N = Nitrogen.
Figure 5. The bioactive compounds that inhibit α-glucosidase enzyme activity.
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2.4. Bioactivity Confirmation and Quantification of Some Bioactive Compounds
A further investigation was required to confirm the bioactivity of afore-mentioned identified
compounds through testing of the individual compounds on α-glucosidase inhibitory activity.
However, not all the compounds could be tested and quantified due to a limitation of the availability
of some of these compounds. Therefore, three bioactive compounds were procured and tested.
These include palmitic acid, heptadecanoic acid, and stigmasterol. The α-glucosidase inhibitory
activity of these compounds was analyzed, and the IC50 values were displayed in Table 3. In many
cases, the purified compounds were observed to have diminished their bioactivities after separation
or purification from the biologically active extract [30]. However, from the results obtained,
these compounds showed fairly good α-glucosidase inhibition activity as an individual compound in
their purified state.
Table 3. The half maximal inhibitory concentration (IC50) of α-glucosidase inhibitory activity of
quantified reference compounds.
Samples
IC50 Value
µg/mL µM
Palmitic acid 24.09 ± 0.44 c 93.95
Heptadecanoic acid 26.10 ± 0.77 b 96.51
Stigmasterol 65.31 ± 0.37 a 158.25
Quercetin 5.77 ± 1.01 19.09
Data expressed as mean ± SD (n = 6). SD = Standard Deviation. Means that do not share a letter are significantly
different with p value < 0.05.
Quantification of each identified compound through GC-MS was carried out to determine the
amount of the identified α-glucosidase inhibitors that is present in the active extract (H) of the C. nutans
leaves extract. An internal standard, methyl nonadecanoate was used to calculate the recovery during
GC-MS analysis. The parameters measured in terms of the linearity, limit of quantification (LOQ),
and limit of detection (LOD) are displayed in Table 4. Besides that, the calibration curves established
were found to be valid with the coefficient of the regression > 0.99 for all the curves developed for each
of the standard references. The recovery of these compounds was calculated to be 93.07%, based on
the standard curve developed for the internal standard, MND that represents the three quantified
compounds. Overall, the range of LOD values obtained was from 0.31 to 5.00 µg/mg, and the range of
LOQ was from 0.63 to 10.00 µg/mg for all the three compounds.
Table 4. Calibration curves, detection limits and quantification limits measured by GC-MS.
Analytes R2 1
Concentration
(µg/mg Sample) 2
LOD
(µg/mg Sample)
LOQ
(µg/mg Sample)
Palmitic acid 0.99 433.25 ± 22.96 a 2.50 5.00
Heptadecanoic acid 0.99 20.27 ± 1.20 c 5.00 10.00
Stigmasterol 0.99 386.48 ± 21.03 b 0.31 0.63
LOD = Limit of Detection; LOQ = Limit of Quantification. 1 R2 is the correlation coefficient of the equation with
n = 3. 2 Data is expressed as mean ± SD (n = 6), calculated considering % recovery of methyl nonadecanoate
(≥98.0%). Means that do not share a letter are significantly different with p value < 0.05.
2.5. Molecular Docking
Molecular docking was carried out in order to understand the protein-ligand interaction at a
molecular level. Generally, protein is comprised of amino acids linked in a sequence to form the
complex. These amino acids have different properties depending on their side chains, which can
be hydrophobic (aliphatic or aromatic), polar (neutral) or even electrically charged (acidic or basic).
This has been the key to the actual properties and behaviors of a protein [31]. All the compounds
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identified to be actively responsible for the α-glucosidase inhibition were docked to the Saccharomyces
cerevisiae isomaltase (SCI) crystal structure (PDB ID: 3A4A). The conformations displaying the lowest
binding energy for the compounds with the interacting residues are summarized in Tables 5 and 6.
Table 5. Molecular interaction results of α-glucosidase enzyme protein with the known inhibitor
(Quercetin) and the active compounds quantified using GC-MS.
Compound Binding Energy(kcal/mol) H-bond Interacting Residues
Other
Interacting Residues
Control ligand −6.00
ASH69, HIE112, GLN182,
ARG213, ASH215, GLH277,
HIE351, ASP352, ARG442
TYR72
Quercetin −8.15 LYS156, THR310, PRO312,LEU313, GLU411, ASN415 PHE314, ARG315
Palmitic acid −3.75 LYS156, LEU313, ARG315 HIE280, PHE314
Heptadecanoic acid −3.80 LYS156, SER236, GLN239, SER240 ARG315
Stigmasterol −8.66 THR290 TRP15, ILE262, ARG263,ILE272, VAL266, HID295
Table 6. Molecular interaction results of other tentative metabolites docked onto α-glucosidase enzyme.
Compound Binding Energy(kcal/mol)
H-bond
Interacting Residues Other Interacting Residues
1-linolenoylglycerol −4.76 LYS156, SER241 TYR158, SER240, PHE314
1-monoplamitin −4.01 TYR158, SER240, ASP242 PHE314, ILE419
Alpha-tocospiro B −7.99 GLN279, GLU411 LYS156, TYR158, PHE159,PHE178, HIE280, PHE314
Glycerol monostearate −3.95 SER241 LYS156, TYR158, SER240, ASP242,PHE314, ARG315, TYR316
Hexadecenoic acid
(methyl ester) −4.00 ALA292, ASN259, HID295 VAL266
Pentadecanoic acid −4.42 HID295 VAL266
Phytol −5.51 GLN239, SER240 LYS156, TYR158, VAL232,LEU313, PHE314
Stigmast-5-ene −9.09 - TYR158, LYS156, HIE280, PRO312,PHE314, ARG315, TYR316
According to AutoDock 1.5.6 simulation result shown in Table 5, the α-glucosidase-quercetin
(positive control) inhibitor complex showed −8.15 kcal/mol binding energy containing five hydrogen
bonds with the interacting residues viz., ASH69, HIE112, GLN182, ARG213, ASH215, GLH277, HIE351,
ASP352, ARG442, and hydrophobic interaction with TYR72. Meanwhile, the binding affinity of palmitic
acid in complex with α-glucosidase was −3.75 kcal/mol. A total of three hydrogen bonds were
observed in the complex involving LYS156, LEU313, and ARG315 along with hydrophobic interactions
involving HIE280 and PHE314. On the other hand, α-glucosidase-heptadecanoic acid complex
showed a binding affinity value of −3.80 kcal/mol. Four residues include LYS156, SER236, GLN239,
and SER240 were observed to interact with heptadecanoic acid via hydrogen bond, while ARG315
was interacting through pi-bond. Despite, interaction with only one residue by hydrogen bond with
its hydroxyl group, THR290, stigmasterol has comparably shown a better binding energy of −8.66
kcal/mol than the positive control quercetin. The hydrophobic contacts seemed to be dominant
in α-glucosidase-stigmasterol complex due to its cyclic skeleton and alkyl groups that preferably
binds to TRP15, ILE262, ARG263, ILE272, VAL266, and HID295. The crystallized ligand, α-D-glucose
(ADG) exhibited slightly lower binding energy; i.e., −6.00 kcal/mol, compared to the positive control,
quercetin, and stigmasterol. However, the hydrogen bonding between ADG and the protein indicates
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a stable interaction with a total of nine bonds, involving ASH69, HIE112, GLN182, ARG213, ASH215,
GLH277, HIE351, ASP352, and ARG442 with a hydrophobic interaction with TYR72. Unlike the docked
ADG, the docking results showed that the binding of the tested compounds are majorly assisted
through hydrophobic contacts with α-glucosidase. The results are comparable to those reported by
Seong et al., [32] who tested the isoflavones where daidzein, genistein and calycosin showed more
hydrophobic contacts with similar residues, such as ILE262, ARG263, ILE272, and VAL266. The 2D
diagram showing the interaction between the compounds and the protein residues are shown in
Figure 6 while the 3D superimposed diagram of the quercetin, ADG, and three reference compounds
(stigmasterol, palmitic and heptadecanoic acid) is displayed in Figure 7.
Figure 6. The 2D diagram showing the interaction between the protein residues and the inhibitors. (A)
Positive control (Quercetin), (B) Palmitic acid, (C) Heptadecanoic acid and (D) Stigmasterol.
Figure 7. The superimposed 3D diagram showing the binding site of the ADG, Quercetin, Palmitic
acid, Heptadecanoic acid and Stigmasterol.
The binding energy and residues involved in the interaction of other tentative metabolites
identified are displayed in Table 6. As for the other α-glucosidase inhibitors identified in this study,
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stigmast-5-ene and alpha tocospiro B displayed better binding energies; i.e., −9.09 and −7.99 kcal/mol
compared to quercetin and ADG. The conformational complex of these compounds is dominantly the
hydrophobic contacts with the residues involved; TYR158, LYS156, HIE280, PRO312, PHE314, ARG315,
TYR316 and LYS156, TYR158, PHE159, PHE178, HIE280, and PHE314, respectively. In fact, the absence
of hydrogen bonding in stigmast-5-ene-α-glucosidase complex may be due to the absence of the
hydroxyl group in the inhibitor. The scenario of prominent hydrophobic contacts is also apparent in
the other tentative metabolites docked onto α-glucosidase, which is possibly due to the hydrophobicity
of the compounds. Overall, the interaction involves hydrogen bonding and other interactions such
as C-H, alkyl, and pi bond, depending upon the nature of the residues interacting to the atoms as
well as the nature of the compounds themselves. All the protein-ligand interactions and the residues
involved were comparable to those seen in the docked positive control-α-glucosidase complexes
and the validation of molecular docking was done by comparing between the crystal structure of
S. cerevisiae isomaltase (PDB ID: 3A4A and its docked crystal ligand, ADG [26,33].
3. Discussion
The α-glucosidase enzyme can be found in the brush-border of the small intestine where its
activity affects the carbohydrate digestion in the human system. During the digestion, starch is
broken down to saccharides (oligo- and di-saccharides), which are then hydrolysed to glucose by
α-glucosidase before being absorbed into the blood circulatory system. Therefore, the α-glucosidase
inhibition is proposed to be an ideal strategy for preventing hyperglycemia. This is because it
can prolong the processes of carbohydrate digestion in the intestinal tract, lengthen the duration
of glucose absorption, and consequently lead to a lower postprandial blood glucose level [34,35].
Plant metabolites have provided a wide array of pharmacological benefits to human health [36].
In most bioactivity analysis, in vitro techniques are utilized to identify the pharmacological potency of
the plant metabolites. Generally, various antidiabetic mechanisms are tested via in vitro procedures,
which include α-glucosidase inhibition activity assay as well. The bioactivity of plant metabolites
depends on the chemical structure, particularly the number and positions of the active functional
groups (e.g., hydroxyl, acetyl) as well as the nature of the substitutions on the aromatic rings [1].
In recent times, research using medicinal plants has been an on-going effort due to the vast variety
of metabolites distributed in plants that may have various health benefits. Numerous organic solvents
and water have been used to extract the potential metabolites from plants. The variation in the solvent
polarity resulted in remarkably different bioactivities and phytochemical constituents. Therefore,
solvents of different polarity were used in this study to obtain C. nutans leaves extracts to evaluate
the different metabolites that may have different polarity thus exhibiting different potential in the
α-glucosidase inhibition assay analysis. The results exhibited an increasing activity with decreased
polarity significantly thus indicating the presence of compounds of less polar nature such as the
terpenoids, sterols and fatty acids group members that are responsible for the inhibition activity [37].
The outcome was influenced by the variability of the metabolites extracted using solvents with
different polarity.
Some of the identified compounds have already been reported to possess α-glucosidase inhibitory
activity. Liu et al. [38] carried out an investigation on the α-glucosidase inhibitory activity of
some fatty acids including palmitic acid. However, the IC50 value of palmitic acid was reported
> 400 µg/mL which was much higher than the value obtained in our study. Apart from palmitic acid,
other fatty acids that are found to be active inhibitors include pentadecanoic acid, heptadecanoic acid,
and hexadecanoic acid (methyl ester). Marella et al. [39] reported these fatty acids in the C. vitalba
formulation, which showed strong antidiabetic activity. Another compound identified to inhibit the
α-glucosidase enzyme activity is phytol. Phytol is an acyclic diterpene alcohol, commonly referred to
as isoprenoids, which is generally produced from the degradation of chlorophyll. The same compound
has already been reported to exhibit strong antinociceptive and antioxidant activities [40]. In a report
Molecules 2018, 23, 2402 12 of 21
by Tundis et al. [41], it was shown that phytol is the most prevailing component contributing to the
strong α-glucosidase inhibiting activity of C. annuum of cerasiferum variety fruits’ hexane fraction.
Plant sterols and its chemical and structural derivatives are secondary metabolites that can be
found ubiquitously in plant parts. Some of the group compounds that were identified in this plant
extract include 1-linolenoylglycerol, glycerol monostearate, and stigmasterol. These compounds are
found to be active against α-glucosidase enzyme in this study. Stigmasterol has been reported to
potentially exhibit hypoglycemic activity by effectively reducing serum glucose level as well as the
activity of hepatic glucose-6-phophatase (G-6-P) with a concomitant increase in insulin concentration
in in-vivo study [42,43]. Besides, stigmasterol isolated from Bacopa monnieri Linn. aerial parts was
reported to have insulin-like activity where its antihyperglycemic effect was suggested to increase
the peripheral glucose consumption as well as protection against oxidative damage in alloxanised
diabetes, which also indicated its antioxidant potential [44]. However, Zareen et al. [45] concluded that
the stigmasterol isolated from Cichorium intybus showed no inhibitory activity against α-glucosidase.
This may be due to the antagonism effect caused by the trace impurities in the isolated compound,
or due to the difference in assay conditions.
Another compound that belongs to the family of monoacylglycerols is 1-monopalmitin (6),
which is a glyceride consisting of one fatty acid chain covalently bonded to a glycerol molecule
through an ester linkage. This study shows that this compound is capable of inhibiting α-glucosidase.
The compound consists of two hydroxyl groups that might contribute to the bioactivity (HMDB) [46].
To our knowledge, there is no scientific report that has ever been published on the α-glucosidase
inhibitory activity of this compound, despite its structural compatibility.
The other compounds that have been found to inhibit α-glucosidase enzyme activity in our study
include stigmast-5-ene, 1-linolenoylglycerol, glycerol monostearate, and alpha-tocospiro B. However,
from the literature, no report has emerged for the α-glucosidase inhibiting activity of these compounds.
Meanwhile, the rest of the compounds identified are the ones assumed to be effectively contributing to
induce α-glucosidase activity via a special mechanism. These compounds include sucrose, maltose,
D-glucose, and D-gluconic acid, which was found inactive in our study.
Despite being claimed by previous studies for its low activity in α-glucosidase inhibition
assay, palmitic acid and stigmasterol in this study have exhibited a good activity. The potential
of these two compounds shall be further investigated for their use in the development as effective
α-glucosidase inhibitors. Hence, the plant leaves extract, due to the presence of aforementioned
α-glucosidase inhibitors, in a significant quantity has a great potential to be used as an efficacious
anti-hyperglycemia remedy.
Generally, all known α-glucosidase inhibitors possess multiple hydroxyl groups that become
the reason for their high activity [32,33]. However, all the compounds identified in our study are
non-polar compounds comprising of sterols, fatty acids, monoacylglycerols, and terpene alcohol.
These compounds are known to possess a minimal amount of the hydroxyl group one or two [47].
Despite this reason, the tested compounds are regarded to have α-glucosidase inhibiting activity
based on the findings above. Moreover, the interactions between the protein and the inhibitors have
suggested the possible conformational complexes that may have caused the positive enzyme inhibitory
activity of the identified compounds.
From the results, it can be deduced that apart from the strong hydrogen bond between the
hydroxyl group of the compounds with the residues possessing polar side chains (GLN and SER)
and electrically charged side chains (ARG, ASP and HIE- protonated HIS), the hydrophobic and
pi-interactions between the compounds cyclic part of the structure and hydrophobic side chains
(TYR, VAL, ILE and PHE) of the enzyme could explain the much higher activities of these non-polar
compounds, which is agreeable to the finding reported by Nussinov [48] and Du et al. [49]. This can be
observed in quercetin as well as other compounds. The residues interacted with ADG and its binding
energy is contributing to its actual catalytic reaction [32,50]. As shown in Table 5, ADG interacted
with ASH215, a conserved residue that acts as the catalytic nucleophile. It also created a hydrogen
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bond with GLH277 (protonated GLU) residue that acted as the general acid-base catalysis. In addition,
ADG also interacted with ASP352, which is responsible for stabilizing the substrate during the catalysis
in order to strengthen the acid-base hydrolysis reaction [32,50].
Besides that, the 3D diagram (Figure 7) also showed that the protein may possess more than one
ligand-binding site, which can offer allosteric control for catalytic activity. This may cause the alteration
to the active site and thus result in the inhibition of the enzyme activity. Allosteric inhibitors have the
ability to fine-tune protein functional activity [49,51]. Generally, allosteric binding ability reflects the
conjugated behavior where conformational perturbations elicited at one region in a macromolecule
affect its active site and thus alters the enzyme activity. Occasionally, any unbound conformation such
as allosteric interactions might be unstable; however, the binding residues may eventually stabilize
it. This may result in the equilibrium shifting toward this conformer or the allosteric ligand that may
display an altered functional site shape [48,52].
Moreover, the superimposed 3D diagram (Figure 7) also suggested that the tested compounds may
exhibit non-competitive inhibition mode compared to the control ligand, ADG, a known competitive
inhibitor [32]. Stigmasterol was observed to be bound away from the active site. Its binding is
dominantly assisted through hydrophobic contacts that contribute to its binding energy thus reflecting
its inhibition activity. This phenomenon may possibly cause conformational changes in the active site of
the enzyme, which may slow down the protein activity [33,48,52]. The stigmasterol’s predicted binding
area could be a promising region for inhibiting this protein activity overall through a non-competitive
mode can be compared with compounds of a similar nature. In addition, due to a lack of hydroxyl
groups in the tested compounds, the hydrophobic and pi-interactions apparently play a greater
role for these compounds’ enzyme inhibitory activity. The binding site of the control ligand on
α-glucosidase was close to the active site pocket, while the others were outside of the pocket indicating
the presence of allosteric binding sites that may possibly alter the enzyme activity. This can be observed
in palmitic acid, heptadecanoic acid, and quercetin binding regions (Figure 7). This arrangement
might induce cleft closure to prevent the entrance of the substrate, which subsequently acts as the
non-competitive inhibiting nature of the metabolites [53]. Generally, these types of inhibitors have
several advantages over the competitive ones since their effect lasts for longer periods of time [54].
It can be highlighted here that, apart from the quantified inhibitors, stigmast-5-ene and alpha-tocospiro
B (binding energies of−7.99 and−9.09 kcal/mol, respectively) showed promising potential as allosteric
in a non-competitive inhibition manner with high hydrophobicity and good binding energy for the
hydrophobic contacts made.
Furthermore, the docking result is also agreeable to what has been reported by Zheng et al. [55]
in their very recent study. The tetracyclic xanthone derivatives that were docked into S. cerevisiae
α-glucosidase enzyme also resulted in similar hydrophobic and pi-interactions between the ligand
and protein observed. Apart from that, another study on docking conducted by Ali et al. [33]
on two plastoquinones, namely sargachromenol and sargaquinoic acid isolated from the active
n-hexane fraction of S. serratifolium, (the IC50 value of 42.41 and 96.17 µM respectively), exhibited
dominantly hydrophobic interactions suggesting that these compounds are allosteric inhibitors against
α-glucosidase. Conclusively, molecular docking in this study has provided supportive data for
α-glucosidase inhibition allowing the prediction of the interaction between α-glucosidase and tested
inhibitors. This can help understanding and virtually visualize the actual scenario of the bioassay
performed at molecular level. Further investigation on other tentative metabolites for their bioassay
activity will be an added advantage to confirm their actual mechanism.
4. Materials and Methodology
4.1. Materials
Organic solvents of analytical grade were purchased from Merck (Frankfurter Strasse, Darmstadt,
Germany). The α-glucosidase (yeast maltase; Saccharomyces cerevisiae) was purchased from Megazyme
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(Bray Co., Wicklow, Ireland). The substrate ρ-Nitrophenyl-ρ-D-glucopyranosidase (PNPG), N-methyl-N
(trimethylsilyl) trifluoroacetamidepurum (97.0%) (GC grade), all reference compounds (quercetin,
palmitic acid, heptadecanoic acid and stigmasterol) and internal standard compounds (methyl
nonadecanoate) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
4.2. Sample Collection
Matured leaves of C. nutans were harvested from Ees Biotech Sdn. Bhd. located at Bukit
Mertajam, Penang, Malaysia. The plant sample was submitted for authentication to the Herbarium
at International Islamic University Malaysia, Kuantan Campus, Malaysia. The specimen’s voucher
number is PIIUM 0238-1. The leaves were washed and dried under shade at room temperature
(25 ± 0.5 ◦C) for a week. The dried leaves were then coursed to powder by using an universal
cutting mill (Fritsch, Idar-Oberstein, Rhineland-Palatinate, Germany) and stored at −80 ◦C prior to
extraction [56].
4.3. Preparation of Extract
The dried C. nutans leaves were macerated in 80 % methanol using the sample to solvent ratio
of 1:3 (w/v) for 3 days where the solvent was changed each consecutive day. The crude extract was
carefully filtered using Whatman filter paper No.1 followed by solvent evaporation using a rotary
evaporator (Büchi, Flawil, Switzerland) under reduced pressure at 40 ◦C. Further maceration was
subjected to the dried crude extracts using different solvents with different polarities, ranging from
hexane, hexane: ethyl acetate (1:1, v/v), ethyl acetate, ethyl acetate: methanol (1:1, v/v), and finally
methanol with the sample to solvent ratio of 1:3 (w/v). Again, all the extracts were then filtered and
dried using rotary evaporator followed by freeze drying process to remove the remaining moisture.
The extracts were prepared in six replicates and stored at −80◦C prior to further analysis. Each extract
was tested for α-glucosidase inhibitory activity and analyzed using GC-MS [56,57].
4.4. α-Glucosidase Inhibition Assay
The α-glucosidase inhibitory activity assay was performed based on the protocol mentioned by
Javadi et al. [1] which mimics the condition of intestinal fluid. Quercetin (1 mg/mL) was used as a
positive control, a known α-glucosidase enzyme inhibitor, and ρ-Nitrophenyl-ρ-D-glucopyranosidase
(PNPG, 0.3 mg/mL) was used as substrate. Accurately, 10 µL of the samples, quercetin, and negative
control (solvent) were transferred into 96-well plate. The reaction mixture of samples and control
contain 100 µL of 30 mM phosphate buffer and 15 µL of α-glucosidase (0.02 U/µL) type one from
Saccharomyces cerevisiae. Meanwhile the blank consists of 115 µL of the buffer without the enzyme.
Both sample and blank mixture were then treated with 75 µL of PNPG after 5 min of incubation
at room temperature. The reaction was stopped using glycine (pH 10) after another 15 min of
incubation. The amount of ρ-nitrophenol released from PNPG was measured using microplate
reader (Tecan Nanoquant Infinite M200, Mannedorf, Zurich, Switzerland) at 405 nm. The half-maximal
inhibition concentration (IC50) value was determined using linear regression analysis based on the
absorbance of the stock solution dilutions for both samples and controls. The determination of IC50
value is an informative measure of a reactant’s efficacy and potency whereby it indicates the amount
of the reactant or inhibitor required to reduce the response by half [37]. All determination was done in
triplicates. The inhibitory activity (%) of each extract was calculated using the following formula:
Inhibitory activity (%) = [(Acontrol − Asample)/Acontrol] × 100% (1)
where, Acontrol is the absorbance of the negative control, and Asample is the absorbance of sample or
positive control.
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4.5. Derivatization Procedure
The samples were derivatized prior to injection into GC-MS as described by Javadi et al. [1].
The sample extract of 25 mg was weighed in a 2 mL centrifuge tube, dissolved in 50 µL of pyridine
and sonicated (Elma, S 30H Ultrasonic, South Orange, NJ, USA) for 10 min at 30 ◦C. As much as
100 µL of methoxyamine HCl (20 mg/mL in pyridine) were added to the sample solution and vortexed.
The mixture was then incubated for 2 h at 60 ◦C in an incubator shaker (Innova 4000-M1192, Weender
Landstr, Goettingen, Germany). Then, the tube was incubated for another 30 min at 60 ◦C after the
addition of 300 µL of N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA). Finally, the sample
solution was filtered using a syringe filter and covered with aluminum foil and left to stand overnight
at room temperature (25 ± 0.5 ◦C) prior to injection into the GC-MS.
4.6. GC-MS Analysis
GC-MS analysis was performed following the method described by Javadi et al. [1] with slight
modification. One micro liter of derivatized sample was injected in the split mode with the ratio
of 10:1 into the GC-MS system, which consisted of an Agilent 6890 GC-MS (Agilent Technologies,
Santa Clara, CA, USA) and a HP 5973 mass selective detector (Agilent Technologies). The GC column
used for the analysis was a DB-5MS 5% phenyl methyl siloxane column with an inner diameter (ID)
of 250 µm and a film thickness of 0.25 µm (Agilent Technologies, Santa Clara, CA, USA). The initial
oven temperature was set to 190 ◦C for 30 min, and then increased to a target temperature of 300 ◦C in
10 min at a rate of 5 ◦C/min and again raised to 320 ◦C in 10 min at a rate of 10 ◦C/min. Helium was
used as the carrier gas with flow rate of 1 mL/min. The injector and ion source temperatures were
set to 250 and 280 ◦C, respectively. Mass spectra were acquired using a full scan and a monitoring
mode with a mass scan range of 50 to 550 m/z. The spectra for each of the chromatogram peaks
were compared with those in the NIST14 database library. The chromatogram and mass spectra were
processed using an Agilent ChemStation, Automated Mass Spectral Deconvolution and Identification
System (AMDIS) and Agilent’s Deconvoluted Reporting Software (DRS).
Data pre-processing was carried after GC-MS analysis where all raw chromatograms were
converted into cdf format using ACD/Spec Manager v.12.00 (Advanced Chemistry Development,
Inc., ACD/Labs Ontario, Toronto, ON, Canada). A further pre-processing procedure extracted
all the related information from the raw data and converted it to a data matrix, which includes
systematic noise filtering, automatic peak detection, baseline correction, data binning, deconvolution,
and chromatographic alignment were done using MZmine software (version 2.3, Okinawa Institute of
Science and Technology Graduate University, Kunigami-gun, Okinawa, Japan) [58]. Finally, the data
were summarized into an Excel sheet form prior to multivariate data analysis.
4.7. Quantification of Active Phytoconstituents
Quantification of the active inhibitory compounds was carried out using the GC-MS according to
the methods described by Salimon et al. [59] and Shailajan et al. [60] with some modifications. The three
reference compounds that were available readily in-house were palmitic acid (S1), heptadecanoic acid
(S2) and stigmasterol (S3). Quantification of each identified compound was carried out to determine
the amount of the identified α-glucosidase inhibitors present in the active extract of the C. nutans
leaves extract. The parameters measured in terms of the linearity, limit of quantification (LOQ) and
limit of detection (LOD) are displayed in Table 4. The LOD and LOQ were determined by ratio of
noise to signal, 1:3 and 1:10 respectively.
4.7.1. Development of Standard Curve of the Reference
Firstly, the standard curve was developed for the reference compounds (S1, S2 and S3).
The derivatized reference solutions were prepared by dissolving 1 mg in 50 µL pyridine and 100 µL
methoxyamine hydrochloride that was added to the mixture before it was allowed to incubate at
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60 ◦C for 2 h prior to the addition of 300 µL of MSTFA to complete the derivatization procedure.
The stock solution of the derivatized reference was further diluted using pyridine with a dilution
factor of 2 (1 mg/450 µL, 0.5 mg/450 µL, 0.25 mg/450 µL and 0.125 mg/450 µL derivatized solution)
before the injection of 1 µL of the solution into GC-MS. The standard curve was prepared based on the
peak area of the reference from the resulting chromatogram, whereby a linear regression equation was
obtained (y = mx + c), with its linearity (R2) ≥ 0.90.
4.7.2. Determination of LOD and LOQ Concentration
Limit of detection (LOD) and limit of quantification (LOQ) were also determined for the reference
compounds and the internal standard right after the series of dilution analyses. Each reference
compound was prepared by dissolving 1 mg of the reference in 8 µL pyridine and 16 µL of
methoxyamine hydrochloride added and followed by 48 µL of MSTFA after the incubation
period. All three derivatized references were mixed and further diluted with a dilution factor of
2 (0.5 mg/72 µL, 0.25 mg/72 µL, 0.125 mg/72 µL derivatized solution, etc.) prior to injection into
GC-MS. LOD and LOQ were determined by ratio of noise to signal, 1:3 and 1:10, respectively.
4.7.3. Determination of Recovery of the Internal Standard (Methyl Nonadecanoate)
Development of Standard Curve of the Internal Standard
The derivatized internal standard solution was prepared following the routine derivatization
method mentioned in Section 2.5. The stock solution of the derivatized internal standard was further
diluted using pyridine with a dilution factor of 2 (12.5 mg/450 µL, 0.5 mg/450 µL, 0.25 mg/450 µL,
and 0.125 mg/450 µL derivatized solution) and each was injected into the GC-MS. The standard curve
was then prepared based on the peak area of the internal standard from the chromatogram with a
regression line possessing linearity of more than 0.90.
Calculation of the Recovery of the Internal Standards
In order to calculate the recovery of the internal standard (IS) in the sample representing the three
quantified compounds overall, the plant sample was spiked with the internal standard and derivatized
before GC-MS analysis. About 24 mg of the plant extract (hexane) was weighed with 1 mg of the
internal standard (W1) dissolved in 50 µL pyridine and further treated following the procedure as
mentioned above. About 1 µL of the derivatized reference solution was injected into GC-MS and
the recovered amount of the internal standard (W2) was calculated by substituting its peak area into
the regression equation obtained from its standard curve. The compound recovery was reported as
percentage of recovery following the equation below:
R (%) = (W2/W1) × 100% (2)
4.7.4. Determination of Targeted Metabolites Concentration in the Sample
The concentrations of the targeted metabolites in the plant extract were determined by preparing
the derivatized plant extract as per above with 25 mg of the extract and 1 µL of the prepared extract
was injected into GC-MS. The peak area of each of the targeted metabolites was obtained from the
chromatogram and the concentration (x) was calculated using the regression equation developed from
the reference standard curve by substituting the peak area [60].
4.8. Molecular Docking
A 1.6 Å resolving crystallographic structure of yeast α-glucosidase; Saccharomyces cerevisiae
isomaltase (SCI) obtained from Protein Data Bank (PDB) (http://www.rcsb.org/pdb/explore/explore.
do?structureId=3a4a; PDB code: 3A4A) was selected as the receptor in this molecular docking.
The receptor was selected based on the sequence similarity of its amino acid residues between the
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target protein and the template (3a4a) was reported to be 71.92%. The 3D structure of positive
control (quercetin) and active compounds identified in GC-MS metabolomics multivariate analysis was
obtained from Pubchem (National Center for Biotechnology Information (NCBI), Bethesda, MD, USA)
and Chemspider (Royal Society of Chemistry, Milton Road, Cambridge, UK). All the water molecules
were removed from the protein structure using the AutoDockTools (The Scripps Research Institute,
La Jolla, CA, USA) of the version 1.5.6 [61]. Prior to the molecular dockings, the homology model of
the enzyme was developed according to the assay condition with pH of 6.5 using PDB2PQR Server,
version 2.0.0 (National Biomedical Computation Resource, San Diego, CA, USA) [62] in order, to mimic
the actual condition of the mechanism medium. The docking grid box parameter was set to cover
an area of 126 Å × 126 Å × 126 Å and centered to the protein at coordinate x, y, and z of 21.272,
−0.751 and 18.633, respectively. For the ligands, Gasteiger charges were added, while the rotatable
bonds in the ligand were assigned with AutoDockTools and all torsions were allowed, to rotate.
The docking jobs were performed with AutoDock (version 1.5.6, The Scripps Research Institute,
La Jolla, CA, USA) using the Lamarkian genetic algorithm [63]. A population size of 150 and energy
evaluations of 2,500,000 (medium) were set to generate 50 ligand docked conformations [26,32,53,64].
The 2D diagram showing the interactions between the protein residues and the compounds were
generated using Biovia Discovery Studio (Biovia, San Diego, CA, USA) while the 3D superimposed
diagram of the complex was rendered using PyMOL™ 1.7.4.5 (Schrödinger, LLC, New York, NY, USA).
4.9. Data Processing and Statistical Analysis
The data were represented as mean ± standard deviation (SD), with six replicates using Minitab
17 (Minitab Inc., State College, PA, USA). The p value was obtained from the ANOVA analysis using
the Tukey’s test with p < 0.05 was considered significant. One-way ANOVA with a Tukey comparison
test was used to evaluate the major differences between the samples with a confidence interval of 95%.
As for the multivariate data analysis, the pre-processed data were fed to the SIMCA P+14.0 software
(version 14.0, Umetrics, Umeå, Västerbotten, Sweden) using Partial Least Square (PLS) applying the
UV scaling method. The model was fitted and validated through the permutation test. Finally, the score
scatter and loading plots were produced.
5. Conclusions
This study investigated the potential antidiabetic activity of different C. nutans extracts that
focused on the inhibitory effects of α-glucosidase enzyme carried out based on GC-MS. The hexane
extract exhibited remarkable inhibitory activity. Some of the potential inhibitor compounds in
this extract were identified and docked to show their molecular interactions that supported the
overall results. The molecular interactions of the inhibitors identified with the protein were
predominantly hydrogen bonding involving residues namely LYS156, THR310, PRO312, LEU313,
GLU411, and ASN415 as well as PHE314 and ARG315 residues with hydrophobic interaction.
Conclusively, the docking results have shown the inhibiting activity of the inhibitors as allosteric
binders thus acting as non-competitive inhibitors. The overall results of this study provide scientific
evidences that exhibit the potential of C. nutans in α-glucosidase enzyme inhibition, which can be a
contribution to the development of medicinal preparations, nutraceuticals, or functional foods for
diabetes and related symptoms as well as for further exploration of the plant’s novel therapeutic or
preventive agents for the treatment of diabetes.
Supplementary Materials: The following is available online. Figure S1: Prediction versus observation of IC50
values from all sample. The R2 of the regression line indicates the goodness of fit between experimental
observations and predicted model.
Author Contributions: Conceptualization, N.-I.N.Y. and A.K.; Methodology, V.P.; Software, Z.I. and A.K.;
Validation, Z.I., A.K., F.A., and K.S.; Formal Analysis, A.K.; Investigation, S.M.; Resources, A.K.; Data Curation,
V.P.; Writing-Original Draft Preparation, S.M.; Writing-Review & Editing, Z.I., Q.-U.A., N.-I-N-Y-, B.-F.U., F.A.,
Molecules 2018, 23, 2402 18 of 21
K.S., H.E.-S. and A.K.; Visualization, Z.I. and A.K.; Supervision, Q.-U.A., B.-F.U. and A.K.; Project Administration,
N.-I.N.Y., F.A., K.S. and A.K.; Funding Acquisition N.-I.N.Y., F.A., K.S., H.E.-S. and A.K.
Funding: This research was funded by Ministry of Agriculture of Malaysia for NKEA Research Grant Scheme
fund (NRGS SP15-060-0182) and International Islamic University Malaysia for RIGS fund (RIGS 16-293-0457).
H.E.-S. is very grateful to the Swedish Research links grant 2016-05908 (VR for the years 2017–2019) for generous
financial support.
Acknowledgments: We are grateful to the Ministry of Higher Education (MOHE), Malaysia, and the Research
Management Center, IIUM, for providing financial assistance. We are also thankful to the technical staffs of the
Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia, who
assisted us during the analytical process in accomplishing this work. H.E.-S. is very grateful to the support of
ICCBS, University of Karachi.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Javadi, N.; Abas, Q.; Hamid, A.A.; Simoh, A.; Shaari, K.; Ismail, I.S.; Mediani, A.; Khatib, A. GC-MS-based
metabolite profiling of Cosmos caudate Leaves possessing alpha-glucosidase inhibitory activity. J. Food Sci.
2014, 79, 1130–1136. [CrossRef] [PubMed]
2. Deshmukh, C.D.; Jain, A. Diabetes Mellitus: A Review. Int. J. Pure Appl. Biosci. 2015, 3, 224–230.
3. Mohan, P.; Nandhakumar, L. Role of various flavonoids: Hypotheses on novel approach to treat diabetes.
J. Med. Hypotheses Ideas 2014, 8, 1–6. [CrossRef]
4. Shihabudeen, M.S.H.; Priscilla, D.H.; Thirumurugan, K. Cinnamon extract inhibits α-glucosidase activity
and damps postprandial glucose excursion in diabetic rats. Nutr. Metab. 2011, 8, 46. [CrossRef] [PubMed]
5. Loh, S.P.; Hadira, O. In vitro inhibitory potential of selected Malaysian plants against key enzymes involved
in hyperglycemia and hypertension. Malays. J. Nutr. 2011, 17, 77–86. [PubMed]
6. Tee, E.S.; Yap, R.W.K. Type 2 diabetes mellitus in Malaysia: Current trends and risk factors. Eur. J. Clin. Nutr.
2017, 71, 844–849. [CrossRef] [PubMed]
7. Sudha, P.; Zinjarde, S.S.; Bhargava, S.Y.; Kumar, A.R. Potent Alpha-amylase inhibitory activity of Indian
Ayurvedic medicinal plants. BMC Complement. Altern. Med. 2011, 11, 5. [CrossRef]
8. Nair, A.S.; Kavrekar, V.; Mishra, A. In vitro studies on Alpha amylase and Alpha Glucosidase inhibitory
activities of selected plant extracts. Eur. J. Exp. Biol. 2013, 3, 128–132.
9. Arullappan, P.; Rajamanickam, P.; Thevar, N.; Kodimani, C.C. In vitro screening of cytotoxic, antimicrobial
and antioxidant activities of Clinacanthus nutans (Acanthaceae) leaf extracts. Trop. J. Pharm. Res. 2014,
13, 1455–1461. [CrossRef]
10. Putwatana, P.; Sanmanowong, P.; Oonprasertpong, L.; Junda, T.; Pitiporn, A.; Narkwong, L. Relief of
radiation-induced oral mucositis in head and neck cancer. Cancer Nurs. 2009, 32, 82–87. [CrossRef] [PubMed]
11. Sakdarat, A.; Shuyprom, A. bioactive constituents from the leaves of Clinacanthus nutans Lindau. Bioorg.
Med. Chem. 2009, 17, 1857–1860. [CrossRef] [PubMed]
12. Alam, A.; Ferdosh, A.; Ghafoor, K.; Hakim, A.; Juraimi, A.S.; Khatib, A. Clinacanthus nutans: A Review of the
medicinal uses, pharmacology and phytochemistry. Asian Pac. J. Trop. Med. 2016, 9, 402–409. [CrossRef]
[PubMed]
13. Uawonggul, N.; Chaveerach, A.; Thammasirirak, A.; Arkaravichien, T.; Chuachan, C.; Daduang, S.
Screening of plants acting against Heterometrus Laoticus Scorpion venom activity on fibroblast cell lysis.
J. Ethnopharmacol. 2006, 103, 201–207. [CrossRef] [PubMed]
14. Shim, A.Y.; Aziana, I.; Khoo, B.Y. Perspective and insight on Clinacanthus nutans Lindau in traditional
medicine. Int J. Integr Biol 2013, 14, 7–9.
15. Lusia M′ Barek, M.; Hasmadi, M.; Zaleha, A.Z.; Mohd Fadzelly, A.B. Effect of different drying methods
on phytochemicals and antioxidant properties of unfermented and fermented teas from Sabah snake grass
(Clinacanthus nutans Lind.) Leaves. Int. Food Res. J. 2015, 22, 661–670.
16. Peng, T.W.; Wen, P.X.; He, C.J.; Akowuah, G.A. Effect of methanol extract of Clinacanthus nutans on serum
biochemical parameters in rats. J. Appl. Pharm. Sci. 2014, 77, 77–86.
17. Ghasemzadeh, A.; Nasiri, A.; Jaafar, H.Z.E.; Baghdadi, A.; Ahmad, I. Changes in phytochemical synthesis,
chalcone synthase activity and pharmaceutical qualities of Sabah Snake Grass (Clinacanthus nutans L.)
In relation to plant age. Molecules 2014, 19, 17632–17648. [CrossRef] [PubMed]
Molecules 2018, 23, 2402 19 of 21
18. Irondi, E.A.; Oboh, G.; Agboola, S.O.; Boligon, A.A.; Athayde, M.L. Phenolics Extract of Tetrapleura Tetraptera
Fruit inhibits xanthine oxidase and Fe2+-induced lipid per oxidation in the kidney, liver, and lungs tissues of
rats in vitro. Food Sci. Hum. Wellness 2016, 5, 17–23. [CrossRef]
19. Kim, C.S.; Subedi, L.; Oh, J.; Kim, A.Y.; Choi, A.U.; Lee, K.R. bioactive Triterpenoids from the twigs of
Chaenomeles sinensis. J. Nat. Prod. 2017, 80, 1134–1140. [CrossRef] [PubMed]
20. Sharma, I.; Aaradhya, M.; Kodikonda, M.; Naik, P.R. Antihyperglycemic, antihyperlipidemic and antioxidant
activity of phenolic rich extract of Brassica Oleraceae Var Gongylodes on streptozotocin induced Wistar rats.
Springerplus 2015, 4, 212. [CrossRef] [PubMed]
21. Liu, W.; Yin, D.; Li, N.; Hou, X.; Wang, D.; Li, D. Influence of environmental factors on the active substance
production and antioxidant activity in Potentilla fruticosa L. and its quality assessment. Sci. Rep. 2016, 6, 118.
[CrossRef] [PubMed]
22. Kim, H.K.; Verpoorte, R. Sample preparation for plant metabolomics. J. Plant Chem. Biochem. Tech. 2010,
21, 4–13. [CrossRef] [PubMed]
23. Dettmer, K.; Aronov, P.A.; Hammock, B.D. MArse spectrometry-based metabolomics. Mass Spectrom. Rev.
2007, 26, 51–78. [CrossRef] [PubMed]
24. Easmin, A.; Zaidul, I.S.M.; Ghafoor, K.; Ferdosh, A.; Jaffri, J.; Ali, M.E. Rapid investigation of α-glucosidase
inhibitory activity of Phaleria macrocarpa Extracts using FTIR-ATR based fingerprinting. J. Food Drug 2017,
25, 306–315. [CrossRef] [PubMed]
25. Wu, Y.; Chang, W.; Wang, C.; Liang, Y. The use of calibration approaches for quantitative GC/MS
analysis-secobarbital Example. Forensic Sci. J. 2006, 5, 13–19.
26. Wang, K.; Bao, L.; Ma, K.; Zhang, J.; Chen, B.; He, J. A novel Class of α-glucosidase and HMG-CoA reductase
inhibitors from Ganoderma Leucocontextum and the anti-diabetic properties of ganomycin in in KK-Aymice.
Eur. J. Med. Chem. 2017, 127, 1035–1046. [CrossRef] [PubMed]
27. Yawadio Nsimba, R.; Kikuzaki, H.; Konishi, Y. Antioxidant activity of various extracts and fractions of
Chenopodium Quinoa and Amaranthus spp. Seeds. Food Chem. 2008, 106, 760–766. [CrossRef]
28. Eriksson, L.; Byrne, T.; Johansson, E.; Trygg, J.; Vikstrom, C. Multi-and Megavariate Data Analysis Basic
Principles and Applications, 2nd ed.; Umetrics Academy: Umeå, Sweden, 2006.
29. Trivedi, D.K.; Iles, R.K. The Application of SIMCA P+ in Shotgun Metabolomics Analysis of ZIC R© HILIC-MS
Spectra of Human urine-Experience with the Shimadzu IT-T of and profiling Solutions Data extraction
Software. J. Chromatogr. Sep. Tech. 2012, 3, 1–5. [CrossRef]
30. Kuhlisch, C.; Pohnert, G. Metabolomics in chemical ecology. Nat. Prod. Rep. 2015, 32, 937–955. [CrossRef]
[PubMed]
31. Mukesh, B.; Rakesh, K. Review Article Molecular Docking: A Review. Int. J. Res. Ayurveda Pharm. 2011,
2, 1746–1751.
32. Seong, A.H.; Roy, A.; Jung, H.A.; Jung, H.J.; Choi, J.S. Protein tyrosine phosphatase 1b and α-glucosidase
inhibitory activities of Pueraria lobata Root and its constituents. J. Ethnopharmacol. 2016, 194, 706–816.
[CrossRef] [PubMed]
33. Ali, M.; Kim, D.; Seong, A.; Kim, H.R.; Jung, H.; Choi, J. α-Glucosidase and protein tyrosine phosphatase
1b inhibitory activity of plastoquinones from Marine brown alga Sargassum serratifolium. Mar. Drugs 2017,
15, 368. [CrossRef] [PubMed]
34. Lavle, N.; Shukla, P.; Panchal, A. ROLE of flavonoids and saponins in the treatment of diabetes mellitus.
J. Pharm. Sci. Bioscientific Res. 2016, 6, 535–541.
35. Sharma, N.; Verma, M.K.; Gupta, D.K.; Satti, N.K.; Khajuria, R.K. Isolation and quantification of Pinitol in
Argyrolobium Rose Plant, by 1H-NMR. J. Saudi Chem. Soc. 2016, 20, 81–87. [CrossRef]
36. Cencic, A.; Chingwaru, W. The role of functional foods, nutraceuticals, and food supplements in intestinal
health. Nutrients 2010, 2, 611–625. [CrossRef] [PubMed]
37. Aykul, A.; Martinez-Hackert, E. Determination of half-maximal inhibitory concentration using
biosensor-based protein interaction analysis. Anal. Biochem. 2016, 508, 97–103. [CrossRef] [PubMed]
38. Liu, L.; Deseo, M.A.; Morris, C.; Winter, K.M.; Leach, D.N. Investigation of α-glucosidase inhibitory activity
of wheat bran and germ. Food Chem. 2011, 126, 553–561. [CrossRef]
39. Marella, A.; Tanwar, O.P.; Saha, R.; Ali, M.R.; Srivastava, A.; Akhter, M.; Shaquiquzzaman, M.; Alam, M.M.
Quinoline: A versatile heterocyclic. Saudi Pharm. J. 2013, 21, 1–12. [CrossRef] [PubMed]
Molecules 2018, 23, 2402 20 of 21
40. De Moraes, J.; De Oliveira, R.N.; Costa, J.P.; Junior, A.L.G.; De Sousa, D.P.; Freitas, R.M. Phytol, a diterpene
alcohol from chlorophyll, as a drug against neglected tropical disease Schistosomiasis mansoni. PLoS Negl.
Trop. Dis. 2014, 8, 51. [CrossRef] [PubMed]
41. Tundis, R.; Loizzo, M.R.; Menichini, Q. NAtural products as α-amylase and α-glucosidase inhibitors and their
hypoglycaemic potential in the treatment of diabetes: An update. Mini-Rev. Med. Chem. 2010, 10, 315–331.
[CrossRef] [PubMed]
42. Mishra, A.; Verma, A.; Mishra, A.P. A pLant rEview: Butea Monosperma (Lam.) Kuntze. Res. J. Pharm. Biol.
Chem. Sci. 2012, 3, 700–714.
43. Nualkaew, A.; Padee, P.; Talubmook, C. Hypoglycemic activity in diabetic rats of Stigmasterol and
Sitosterol-3-O-α-D-glucopyranoside isolated from Pseuderanthemum Palatiferum Nees Radlk. Leaf extract.
J. Med. Plants Res. 2015, 9, 629–635. [CrossRef]
44. Ghosh, T.; Ghosh, S.; Maity, T.K. Antihyperglycemic activity of Stigmasterol isolated from Bacopa Monnieri
Linn. Aerial parts against Alloxan induced diabetic rats. Int. J. Nat. Prod. Res. 2014, 4, 40–46.
45. Zareen, S.; Choudhary, M.I.; Akhtar, M.N.; Khan, S.N. α-Glucosidase inhibitory Activity of Triterpenoids
from Cichorium Intybus. J. Nat. Prod. 2008, 392, 910–913. [CrossRef]
46. Human Metabolome Database (HMDB). Available online: http://www.hmdb.ca/metabolites/
HMDB0031074 (accessed on 10 December 2017).
47. Kaufman, P.B.; Cseke, L.J.; Warber, A.; Duke, J.A.; Brielmann, H.L. Natural Products from Plants; CRC Press:
Boca Raton, FL, USA, 2000.
48. Nussinov, R. Introduction to Protein ensembles and Allostery. Chem. Rev. 2016, 116, 6263–6266. [CrossRef]
[PubMed]
49. You, X.; Li, Y.; Xia, Y.L.; Ai, S.M.; Liang, J.; Sang, P. Insights into protein-ligand interaction: Mechanisms,
models, and methods. Int. J. Mol. Sci. 2016, 17, 144. [CrossRef]
50. Yamamoto, K.; Miyake, H.; Kusunoki, M.; Osaki, S. Crystal structures of Isomaltase from Saccharomyces
cerevisiae and in complex with its competitive inhibitor maltose. FEBS J. 2010, 277, 4205–4214. [CrossRef]
[PubMed]
51. Lu, A.; Huang, W.; Zhang, J. Recent computational advances in the identification of allosteric sites in proteins.
Drug Discov. Today 2014, 19, 1595–1600. [CrossRef] [PubMed]
52. Guarnera, E.; Berezovsky, I.N. Allosteric sites: Remote control in regulation of protein activity. Curr. Opin.
Struct. Biol. 2016, 37, 1–8. [CrossRef] [PubMed]
53. Yan, J.; Zang, G.; Pan, J.; Wang, Y. α-Glucosidase inhibition by luteolin: Kinetics, interaction and molecular
dolling. Int. J. Biol. Macromol. 2014, 64, 213–223. [CrossRef] [PubMed]
54. Brindis, Q.; Rodríguez, R.; Bye, R.; González-Andrade, M.; Feed, R. (Z)-3-Butylidenephthalide from
Ligusticum porteri, An α-glucosidase inhibitor. J. Nat. Prod. 2011, 74, 314–320. [CrossRef] [PubMed]
55. Zheng, X.; Zhou, S.; Zhang, C.; Wu, D.; Luo, H.B.; Wu, Y. Docking-assisted 3D-QSAR studies on Xanthones
as α-glucosidase inhibitors. J. Mol. Model. 2017, 23, 1–12. [CrossRef] [PubMed]
56. Abd Aziz, A.M.; Low, C.N.; Chai, L.C.; Abd Razak, A.S.N.; Selamat, J.; Son, R. Screening of selected
Malaysian plants against several food-borne pathogen bacteria. Int. Food Res. J. 2011, 18, 1195–1201.
57. Javadi, N.; Abas, F.; Mediani, A.; Abd Hamid, A.; Khatib, A.; Simoh, S.; Shaari, K. Effect of storage time
on metabolite profile and alpha-glucosidase inhibitory activity of Cosmos caudate Leaves-GCMS based
metabolomics approach. J. Food Drug 2015, 23, 433–441. [CrossRef] [PubMed]
58. Pluskal, T.; Castillo, A.; Villar-Briones, A.; Orešicˇ, M. MZmine 2: Modular framework for processing,
visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinform. 2010, 11, 1–11.
[CrossRef] [PubMed]
59. Salimon, J.; Omar, T.A.; Salih, N. An accurate and reliable method for identification and quantification
of fatty acids and trans fatty acids in food fats samples using gas chromatography. Arab J. Chem. 2017,
10, S1875–S1882. [CrossRef]
60. Shailajan, A.; Joshi, H. Optimized Separation and Quantification of Pharmacologically active markets
Quercetin, Kaempferol, β-Sitosterol and Lupeol from Cuscuta Reflex Roxb. J. Pharm. Res. 2011, 4, 1851–1853.
61. Sanner, M.F. Python: A programming language for software integration and development. J. Mol.
Graph. Model. 1999, 17, 57–61. [CrossRef] [PubMed]
Molecules 2018, 23, 2402 21 of 21
62. Dolinsky, T.J.; Nielsen, J.E.; McCammon, J.A.; Baker, N.A. PDB2PQR: An automated Pipeline for the
setup, execution, and analysis of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004,
32, W665–W667. [CrossRef] [PubMed]
63. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking
using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998,
19, 1639–1662. [CrossRef]
64. Lestari, W.; Dewi, R.T.; Kardono, L.B.S.; Yanuar, A. Dolling Sulochrin and Its derivative as α-Glucosidase
inhibitors of Saccharomyces cerevisiae. Indones. J. Chem. 2017, 17, 144–150. [CrossRef]
Sample Availability: Samples of the compounds namely; palmitic acid, heptadecanoic acid and stigmasterol are
available from the authors.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
